CD47 player Trillium chops discovery efforts and 40% of staff; Brii Bio inks deal to bring antibiotics to China
→ One month into his tenure at Canadian microcap biotech Trillium, Jan Skvarka is bringing out the ax as he sorts out the development plans for its CD47 drugs. The restructuring will see the discovery research unit nixed and the headcount will be reduced by 40% (from 43 to 26), reducing the burn rate from CDN$10 million to CDN$4-7 million per quarter. Meanwhile, the company will seek to partner out its preclinical STING agonist program, which it likely doesn’t have enough resources to tend to.
Following a meeting with the FDA, Trillium is also closing a Phase Ib trial in which its drug is administered intratumorally. The dose-escalation study for intravenously administered TTI-621 will now become the sole priority.
→ The infectious disease specialists at Brii Bio have found its next partner in Qpex, which is handing over China development and commercialization rights to a portfolio of antibiotics. The deal covers three products tackling multi-drug resistant gram-negative infections: an IV beta-lactamase inhibitor-based drug, an oral BLI combo, and a next-gen polymyxin.
→ Novo Nordisk $NVO, the world’s largest insulin maker, on Tuesday said the FDA has expanded the label on its fast-acting mealtime insulin Fiasp to allow adult diabetic patients to use Fiasp in their pumps. The product was originally approved in 2017 for use by intravenous infusion under supervision by a healthcare professional or by multiple daily subcutaneous injections.
→ Enterprise Therapeutics’ ion channel R&D work in respiratory diseases just got a boost from the Cystic Fibrosis Foundation, which is awarding up to $7 million for the preclinical and initial clinical development of ETC002. The biotech, backed by Versant and Novartis, is working on a way to hydrate the mucus that builds up in patients’ lungs so that it can be easier to clear — an approach that should work regardless of genetic mutations.
→ Sangamo has notched an orphan drug designation for its gene therapy for Fabry disease after starting a clinical program earlier this year.